These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

649 related items for PubMed ID: 19451504

  • 1. Long-term successful adalimumab therapy in severe hidradenitis suppurativa.
    Blanco R, Martínez-Taboada VM, Villa I, González-Vela MC, Fernández-Llaca H, Agudo M, González-López MA.
    Arch Dermatol; 2009 May; 145(5):580-4. PubMed ID: 19451504
    [Abstract] [Full Text] [Related]

  • 2. Effective long-term control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapy.
    Arenbergerova M, Gkalpakiotis S, Arenberger P.
    Int J Dermatol; 2010 Dec; 49(12):1445-9. PubMed ID: 21091684
    [Abstract] [Full Text] [Related]

  • 3. Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa.
    van Rappard DC, Leenarts MF, Meijerink-van 't Oost L, Mekkes JR.
    J Dermatolog Treat; 2012 Aug; 23(4):284-9. PubMed ID: 21756155
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa.
    Miller I, Lynggaard CD, Lophaven S, Zachariae C, Dufour DN, Jemec GB.
    Br J Dermatol; 2011 Aug; 165(2):391-8. PubMed ID: 21457202
    [Abstract] [Full Text] [Related]

  • 6. Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab.
    Harde V, Mrowietz U.
    J Dtsch Dermatol Ges; 2009 Feb; 7(2):139-41. PubMed ID: 19371236
    [Abstract] [Full Text] [Related]

  • 7. A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa.
    Amano M, Grant A, Kerdel FA.
    Int J Dermatol; 2010 Aug; 49(8):950-5. PubMed ID: 21128923
    [Abstract] [Full Text] [Related]

  • 8. A prospective open-label clinical trial of efficacy of the every week administration of adalimumab in the treatment of hidradenitis suppurativa.
    Sotiriou E, Goussi C, Lallas A, Chovarda E, Apalla Z, Lazaridou E, Ioannides D.
    J Drugs Dermatol; 2012 May; 11(5 Suppl):s15-20. PubMed ID: 22644772
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, Fischkoff SA, Chartash EK.
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of adalimumab in pediatric patients with Crohn disease.
    Wyneski MJ, Green A, Kay M, Wyllie R, Mahajan L.
    J Pediatr Gastroenterol Nutr; 2008 Jul; 47(1):19-25. PubMed ID: 18607264
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy of adalimumab in the treatment of psoriasis: a retrospective study of 15 patients in daily practice.
    Sola-Ortigosa J, Sánchez-Regaña M, Umbert-Millet P.
    J Dermatolog Treat; 2012 Jun; 23(3):203-7. PubMed ID: 21787203
    [Abstract] [Full Text] [Related]

  • 15. Etanercept: effective in the management of hidradenitis suppurativa.
    Cusack C, Buckley C.
    Br J Dermatol; 2006 Apr; 154(4):726-9. PubMed ID: 16536817
    [Abstract] [Full Text] [Related]

  • 16. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.
    Kimball AB, Jemec GB, Yang M, Kageleiry A, Signorovitch JE, Okun MM, Gu Y, Wang K, Mulani P, Sundaram M.
    Br J Dermatol; 2014 Dec; 171(6):1434-42. PubMed ID: 25040429
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa.
    Gulliver WP, Jemec GB, Baker KA.
    J Eur Acad Dermatol Venereol; 2012 Jul; 26(7):911-4. PubMed ID: 21605174
    [Abstract] [Full Text] [Related]

  • 20. Severe refractory hidradenitis suppurativa in an HIV-positive patient successfully treated with infliximab.
    Alecsandru D, Padilla B, Izquierdo JA, Fernández-Cruz E, Sánchez-Ramón S.
    Arch Dermatol; 2010 Dec; 146(12):1343-5. PubMed ID: 21173317
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.